The Status Of New Drug Research And Development Institutions In China And The Thinking About It And Its Future

New drug's research and development is the key for ensuring public health and is the source of Chinese pharmaceutical industry development, its development status has vital influence on the situation of China's pharmaceutical industry at present and in the future. Especially at present, China has just ended WTO transition period, foreign manufacturers have landed in China and will consolidate their overwhelming dominance by taking the strategy of gradually taking sales, production as well as R&D of the locally. The development of new drug research and development institutions that will directly affect our national pharmaceutical industry can survive in a technically independent state or not. This article is to analyze the characteristics of Chinese new drugs R & D institutions' development and put forward rational proposals for the institution development under existing conditions and resources, by the investigating the institutions' status of survival and development.Based on the investigation on some new drug R & D institutions, as well as the analysis of relevant data of the institutions in their own development, such as capital investment, technology transfer, the number and category grading of drug registration, this article summarized and expounded the development status of Chinese new drug R & D institutions.Base on the view of new drug R & D institutions, the current environment for the survival and development of new drug R & D institutions in China was introduced in the aspects of policy environment, capital investment and market environment and the basic classification of drug R & D institutions and their characteristics were deduced. The development status of the new drug R & D institutions was summarized as: innovation strength increased, but the difficulty increased too; overall technological innovation of the field has no apparent progress, in some part even has obvious retrogression; scarcity and waste of drug R & D and innovation resources coexist; lack of reasonable outcome transfer mechanism and necessary cooperation trust between outcome transferor and receiver; survival pressure lead to "short-sighted" act; accumulating weakness exists in the pharmaceutical industries and the situation is becoming worse by forced drug price reduction. The challenges that the new drug R & D institutions will encounter in the future were expounded. They are: new drug development is more and more difficult, cost is higher and higher, time is becoming longer, risk is increasing. Besides, at present the development of new drugs will face the instability of supervision policy, deletion of investment and intellectual property protection mechanism, new drug development ideas and models need change, and so on.According to the development status of the new drug R & D institutions in China and the inspiration of foreign drug R&D institutions' development, the article discussed the strategies of the new drug R & D institution development in the future, and made recommendations based on positively facing to existing development conditions and making full use of existing resources: all types drug R&D institutions should position themselves clearly, educing their advantages, forming systematic cooperation and avoiding repeated investment; cooperate closely with vocation supervision departments to establish systems such as qualification confirmation, recording to the supervision departments, etc; establish a reasonable mechanism in personnel training and incentives, culturing and reserving talented persons; prominent their own characteristics in the choice of research and development projects, and take the professional road; strengthen cooperation with the manufacturing enterprises to make both sides benefit; strengthen academic exchanges to make technological innovation ideas more rich; actively promote international cooperation, and strive to open up international markets.